This study retrospectively analyses the experience with an intensive enteral feeding protocol in children undergoing BMT at the National Paediatric BMT Centre, Our Lady's Hospital for Sick Children, Crumlin, Dublin. Fifty-three patients were transplanted between January 1996 and December 1998; 42 patients received allogeneic transplants, (19 unrelated) and 11 were autologous. Indications included ALL (21), ANLL (3), CML (3), JCML (1), MPS (5), WAS (2), AA/FA (6), NHL/HD (3) and solid tumours (9). Nasogastric (NG) tubes were inserted electively either during conditioning or within the first week when voluntary oral intake had decreased. Nineteen patients were commenced on a whole protein-based formula, 28 on a semi-elemental preparation and two were commenced on an elemental feed. All were maintained on an elemental formula during the period of maximal gut toxicity.Tubes which were vomited were promptly replaced and morphine infusions were routinely employed until mucositis had resolved. Of 49 evaluable patients, 42 (86%) were maintained exclusively on enteral nutrition and seven required parenteral nutrition. Seven patients weighed Ͻ85% ideal body weight (IBW) at discharge (range 75-84), only one of whom was Ͻ85% IBW at 3 months. Twenty-two patients continued on NG feeds following discharge (median 41 days). No patient had veno-occlusive disease. The programme was overwhelmingly endorsed by patients and/or parents but required intensive multidisciplinary counselling to ensure success. Bone Marrow Transplantation (2001) 27, 741-746. Keywords: enteral feeding; children; BMT Bone marrow transplantation (BMT) is recognised as standard therapy for patients with high risk leukaemia and a variety of stem cell disorders ranging from immunodeficiencies to inborn errors of metabolism. [1] [2] [3] [4] The catabolic effects of high-dose chemotherapy, total body irradiation
(TBI) and graft-versus-host disease (GVHD), combined with limited oral intake in the peritransplant period due to anorexia, nausea, vomiting and multiple organ dysfunction, necessitate an intensive approach to nutrition support.
Parenteral nutrition (PN) has been considered traditionally the method of choice for providing nutritional support for patients undergoing BMT, [5] [6] [7] although there are no data to support the theory that haematological and immunological recovery are accelerated by intravenous feeding. Total parenteral nutrition (TPN) is more likely to lead to complications including volume overload, hyperglycaemia, venous thrombosis and infection. 8, 9 The financial cost of intravenous feeding, while of secondary importance, adds an additional burden to an already costly programme. 9, 10 Animal 11 and human 12, 13 studies have demonstrated the beneficial effects of enteral feeding on the gut mucosa. Its tolerance and efficacy in paediatric BMT patients have previously been explored 14 and recent reports are encouraging. 15, 16 The Department of Haematology and Oncology at Our Lady's Hospital for Sick Children, Dublin has employed, in recent years, an intensive enteral feeding protocol as standard practice for all patients undergoing transplantation. This report retrospectively analyses the experience.
Patients and methods
All patients undergoing BMT at the Irish National Paediatric BMT Centre between January 1996 and December 1998 were incorporated into the study. Case records, including medical, nursing and dietetic data were reviewed. Indications for and nature of transplant are documented in Table 1 . There were 31 males and 22 females. Age range was 0.5 to 17.5 years with a mean of 7.6 years (median 7.3 years).
Conditioning regimens
All patients with acute lymphoblastic leukaemia (ALL), acute non-lymphoblastic leukaemia (ANLL) and chronic myeloid leukaemia (CML) over the age of 2 years were conditioned using cyclophosphamide and total body irradiation (TBI) -750 cGy to those receiving HLA-identical related transplants and 1440 cGy in eight fractions to unrelated transplant recipients. In addition, patients receiving unrelated grafts were T cell-depleted in vivo using Campath 1G monoclonal antibody. Patients with mucopolysaccharoidosis (MPS), Wiskott-Aldrich syndrome (WAS) and leukaemia under 2 years received busulphan/ cyclophosphamide with melphalan given in addition to Bu/Cy to the single patient with juvenile chronic myeloid leukaemia (JCML). Patients with aplastic anaemia (AA) were conditioned using cyclophosphamide and anti-thymocyte globulin while those with Fanconi anaemia (FA) received cyclophosphamide. Patients with solid tumours undergoing autologous transplantation received high-dose melphalan and patients with lymphoma were conditioned with BEAM.
Antimicrobial policy
All patients were nursed in isolation in a laminar flow cubicle until engraftment had been documented. Oral hygiene was maintained with chlorhexidine mouthwash and gut decontamination was not employed. Cotrimoxazole, was commenced by mouth daily until patients became neutropenic and recommenced when engraftment had been documented. Acyclovir and fluconazole were commenced at the start of conditioning and continued at least until day +30. Febrile neutropenic patients were commenced on piperacillin/tazobactam and amikacin; liposomal amphotericin (Ambisome, Nextar Pharmaceuticals, Cambridge, UK) was added if fever failed to resolve within 48-72 h.
Graft versus host disease prophylaxis
All patients received cyclosporin and short-course methotrexate was given to patients receiving unmanipulated grafts. Bone marrow from unrelated donors was T celldepleted ex vivo using Campath 1M and complement with the exception of CML, JCML and MPS patients whose grafts were T cell-replete.
Veno-occlusive disease (VOD) prophylaxis
All patients undergoing allogeneic transplantation were given ursodeoxycholic acid (ursodiol) 10 mg/kg daily by mouth from the start of conditioning to day 30 post transplant; this was continued if liver function tests (LFTs) were abnormal.
Assessment of nutritional status
Weight and height pre-BMT, at discharge and at 3 and 6 months post transplant were recorded and percentage of ideal body weight (% IBW) calculated for each patient. IBW was calculated by noting the age at which the child's actual height plotted on the 50th centile, using the Irish National Growth Chart;
17 the weight at the 50th percentile for this age was taken as 100% IBW. 18 Weight was measured on an electronic scale (model 708; Seca, Hamburg, Germany), while a stadiometer (model 220, Seca) was used to measure height. Nutritional status was based on the recommendation of Ringwald-Smith et al 19 which defines adequately nourished as a weight of Ͼ85% of IBW. Wellbeing was assessed at 3 and 6 months and graded using the Lansky performance scoring system. 20 
Nutrition
Nasogastric (NG) tubes were inserted routinely in patients undergoing BMT; these were inserted electively either during conditioning or within 1 week of transplant when voluntary oral intake had decreased. Enteral nutrition (EN) was administered via a standard feeding pump. Patients were commenced on a whole protein or semi-elemental feed and changed to an elemental preparation (see Table 2 for details of nutrition) if there was clinical evidence of increasing gastrointestinal (GI) toxicity as evidenced by vomiting and diarrhoea, usually by the end of the first week. Feeds were commenced initially overnight but continued by day, as oral intake decreased. NG volumes were commenced at 10-30 ml/h and increased gradually as tolerated; feeds were administered usually on a cycle of 4 consecutive hours, followed by a rest period of 1 hour and then recommenced for a further 4 hours. As vomiting and diarrhoea abated and appetite gradually improved, feeds were administered mainly overnight. Changes between whole protein/semielemental/elemental feeds were individualized and guided by the degree of GI toxicity. Episodes of vomiting and diarrhoea were recorded and graded as mild (Ͻ3 per day), moderate (3-6 per day) and severe (Ͼ6 per day). Tubes which were vomited were promptly replaced; care was taken in such patients to ensure that platelet counts were adequate prior to the procedure. The volume of NG feeds was calculated on a weekly basis by reviewing daily fluid balance charts and dietetic records. The estimated average requirement (EAR) in kcal/kg was calculated for each patient using the age and IBW. Feeding was continued, even when diarrhoea was severe, but the volume titrated down to the maximum tolerated; in such circumstances, fluid balance was maintained by intravenous dextrose/saline infusion. Parenteral nutrition (PN) was commenced (1) if vomiting and/or diarrhoea increased to an intolerable severity and showed no sign of abating over a 3 to 4 day period and (2) in the presence of documented severe gut GVHD.
All patients who were old enough (usually over the age of 2 years) were counselled on an ongoing basis by a multidisciplinary team. The immediate family formed an essential component of ongoing support. Discussion with patients who had previously experienced such a regimen and their parents was also encouraged. All patients were prescribed regular analgesia, usually in the form of morphine infusion, until mucositis had resolved and all were prescribed ondansetron 2-8 mg on an 8 h basis, alternating also 8 h with metoclopramide 1-10 mg, as indicated.
Laboratory investigations
Daily full blood count (FBC), urea and electrolytes were routinely performed and serum bilirubin, transaminases alkaline phosphatase, serum proteins, creatinine, inorganic phosphate and coagulation screen monitored twice weekly. All patients had a twice weekly microbiological screen, including all central venous catheter ports, throat, skin, urine and stool cultures. Peripheral venous cultures were taken if the temperature exceeded 38°C and blood cultures were repeated every 48 h in the presence of persisting fever.
Results
Two patients experienced graft failure after unrelated donor transplant, one of whom received a second graft from the same donor and one who underwent autologous infusion of previously harvested remission marrow; both patients died. Two further patients died of CMV pneumonitis following unrelated BMT. All four patients died within 6 weeks of transplant and, for the purpose of this study, are excluded from analysis. Eighty-six percent of patients in this study were managed exclusively on EN, 8% of whom did not warrant NG feeding as an adequate oral intake was maintained. Three out of 45 patients fed nasogastrically weighed Ͻ85% (75-83) of their IBW immediately prior to transplant; mean weight for the entire group was 101% IBW. NG feeding was commenced at a mean of 3 days from transplant (range day −4 to day +11) and four patients had Bone Marrow Transplantation been commenced on NG supplemental feeds prior to conditioning. Nineteen patients were commenced on a whole protein feed, while 28 were given a peptide-based formula and two children were commenced on elemental feeds.
The incidences of vomiting and diarrhoea are documented in Figure 1 . Vomiting was mild in the majority of patients and was experienced by most patients within the first week. This was mainly attributable to adjustment to the NG tube and was minimal by week 5. Nasogastric tubes which were vomited were promptly replaced; this occurred mostly within the first 2 weeks of transplant and coincided with the period of maximal gut toxicity. As platelet transfusions were administered prior to replacement, there was no related epistaxis. The incidence of diarrhoea, not surprisingly, was greatest in weeks 2 and 3, but persisted in 14 patients after week 6.
The mean percentage of the estimated caloric requirement provided by NG feeds increased from 37% in week 1 to 48% in weeks 2 and 3; by week 6 this was reduced to 33%. The mean % IBW at discharge was 97% (range 75-104); seven patients out of 49 weighed Ͻ 85% of IBW (range 75-84) at discharge. NG feeds were maintained a median of 52 days (range 5-267 days). Twenty-two patients continued on NG feeds following discharge (median 41 days). Only one patient was still Ͻ85% IBW 3 months following transplant despite receiving PN for 42 days; at 6 months, she was still Ͻ85% IBW. This patient had received a non-TBI conditioning regimen. Six additional patients required PN (median 8 days), only two of whom had received TBI. Patients were discharged a mean of 37 days (median 29) following transplant (range 15-150 days). Engraftment of neutrophils was documented a mean of 20 days (range 9-44) and platelets a mean of 47 days (range 12-148) following transplant which was comparable to historical controls (data not shown). Weights compared favourably also with historical controls, most of whom received parenteral nutrition, even despite the fact that more unrelated donor transplants were performed during the period of this study. Mean Lansky score for all patients, excluding the MPS group, was 80 at 3 months and 90 at 6. Hypomagnesaemia was observed in 23 out of 49 patients in weeks 2 and 3; 17 patients were treated with oral magnesium supplements and six required i.v. replacement as oral treatment was not tolerated. Ten patients required i.v. phosphate replacement. Hypoalbuminaemia (Ͻ36 g/l) was documented in 16 patients (range 27-34 g/l), six of whom developed levels below 32 g/l. Levels had reverted to normal in all but one patient by week 6. Thirty-eight patients had mildly abnormal LFTs (twice normal values) which were maximal between weeks 2 and 3, only two of whom had major (Ͼ three times normal values) hepatic dysfunction; both patients had GVHD of gut and liver. No patient developed coagulopathy and none had VOD.
Eleven patients had central venous catheter line infections (seven Staphylococcus epidermidis, two Escherichia coli, two Stenotrophomonas maltophilia), two of whom were receiving TPN. Four patients had positive blood cultures (one Staphylococcus epidermidis, one Streptococcus viridans, one E. coli and one Stenotrophomona maltophilia), two of whom were also receiving TPN. Seventeen patients developed febrile neutropenia, for which no organism was identified. Three patients had an E. coli urinary tract infection. Four patients had positive stool cultures, Rotavirus (one), toxin positive Clostridium difficile (two), Giardia lamblia (one) and Campylobacter jejuni (one). There were no oropharyngeal or sinus infections.
Discussion
This study has demonstrated that an aggressive enteral feeding programme, supported by a committed team, can maintain nutritional status in a paediatric BMT population. The fact that more than 50% of patients in this study had received TBI is noteworthy. In general, NG feeds were well tolerated and compliance was excellent. While the overwhelming majority of parents welcomed this pre-emptive approach to feeding, some older patients were initially reluctant to embark on such a regimen. However, with additional encouragement and support, these children also were converted as weight in general stabilised. With recovery of appetite, supplemental feeding was reduced in most cases to night feeds only. The routine use of morphine infusions and antiemetic agents undoubtably facilitated the maintenance of this programme. Continuation of feeds following discharge was welcomed by both parents and patients and, in the authors' opinion, accelerated recovery and improved general wellbeing.
Nutritional status had been within normal range in most patients with all but three in the study population Ͼ85% IBW immediately prior to transplant; this was attributable to the fact that all patients in this unit are commenced on supplemental NG feeding, if weight falls by more than 10% of their admission value while receiving chemotherapy.
This pre-emptive approach is in keeping with practice elsewhere. [21] [22] [23] It seemed logical, therefore, that a policy of NG feeding would be continued in the peritransplant period.
Nutrition was assessed clinically by weight and weight for height; others have incorporated mid arm circumference 15, 23 and body composition analysis by radioisotope dilution techniques. 9 As weight was monitored at least once daily, changes secondary to fluid overload were readily detected. Despite the fact that NG feeds provided less than 50% of caloric requirements throughout the peritransplant period, weight was maintained in most patients. Papadopoulou et al 15 reported a mean energy intake by NG feeds of 48%. In that study, 8/21 BMT patients fed on a NG diet were regarded as treatment failures either because tubes were vomited or patients had diarrhoea; six of those patients were subsequently commenced on TPN. In contrast to this study, more than 50% of patients had poor nutritional status prior to BMT. Oral intake, as in this study, was not measured because of erratic documentation and mean duration of NG feeds was 22 days. Twenty-two patients in this study continued on NG feeding, usually overnight, following discharge; this was mainly attributable to persistent anorexia and fatigue, particularly after TBI conditioning regimens and was usually at the request of patients and parents.
In contrast to others, 15 oral mucositis was not regarded as a contraindication to enteral feeding; routine incorporation of morphine infusions added greatly to patient comfort and facilitated regular oral hygiene. Some authors have suggested that the risk of bleeding and infection are increased if EN is continued when mucositis develops; 24 no such observations were documented in this study as platelet transfusions were given prior to reinsertion of NG tube, if the platelet count was Ͻ20 × 10 9 /l. An added advantage of enteral feeding was the ease of administration of oral medications, all, with the exception of cyclosporine, given via the NG tube. Patients were commenced on a high calorie diet, if tolerated, and changed to a low residue, low fat, lactose-free elemental diet if diarrhoea was severe. Using this approach, GI toxicity was tolerable and less severe than was previously reported in a similar group of parenterally fed patients. 25 Others have documented a lower incidence of diarrhoea in patients on enteral feeding in comparison with a TPN group.
14 Enteral feeding has a trophic effect on the gut 26 and continuation of NG feeding during the period of maximal gut toxicity may accelerate healing. EN has also been documented to maintain mucosal integrity, supporting the barrier function of the gut and thereby reducing the risk of bacterial translocation. 13, 27 This is in contrast to TPN where there is a reduction of luminal mucous gel, thereby increasing the permeability of the small intestine. 28 Diarrhoea following transplant may be associated with a protein losing enteropathy. 29 This may well explain the low serum albumin noted in 16 patients in this study, all but one of whom had regained normal values by week 6. As in other studies, the incidence of hypomagnesaemia was significant and greater than previously noted in patients receiving TPN. 9 Mechanisms of hypomagnesaemia are multifactorial and have been documented irrespective of infections or diarrhoea; 15 intracellular migration secondary to cyclosporine has also been implicated. 30 In children with Crohn disease, Mg loss in stools has been observed and has been attributed to absorptive defects in an inflamed gut. 31 Trace elemental deficiency, most notably copper, zinc and selenium have also been reported following transplant, possibly related to tubular dysfunction, 32 resulting in increased peritransplant morbidity. 33 While trace elements were not monitored in this study, all NG formulae were nutritionally complete.
Glutamine which accounts for 25% of the amino acid pool provides up to 40% of the energy requirements within the bowel. 34 Endogenous production is adequate under normal circumstances but becomes inadequate in catabolic states. 34 Recent data have shown that glutamine supplemented parenteral and enteral nutrition following BMT improves intestinal mucosal integrity and maintains villus height. 35 Data are conflicting, however, as to whether glutamine alters the incidence of infection secondary to bacterial translocation. [36] [37] [38] It is unstable in solution, necessitating addition immediately prior to use. 39 No formal policy of glutamine supplementation was undertaken at the time of this study. Future randomised trials are indicated to address its usefulness in an enterally fed BMT population.
Apart from two patients with CML who developed severe GVHD of gut and liver following non-T cell-depleted unrelated transplants, no other patients in this study developed severe hepatic dysfunction or VOD despite the fact that many were conditioned with busulphan conditioning regimens, an acknowledged associated risk factor. 40 All patients undergoing allogeneic transplantation in this study received ursodiol prophylactically which may have influenced the risk for VOD. 41 It is also possible, however, that intensive enteral support reduced cholestasis during this critical period.
The increased effectiveness of 5HT 3 antagonists in reducing nausea and vomiting provides further support for a policy of enteral nutrition in most BMT patients. Failure to gain weight, resulting from inadequate oral intake which often results from persistent anorexia and absence of taste which may last for weeks after transplant, is obviated by continuation of NG feeds following discharge. The considerable cost saving of an enteral vs parenteral nutrition programme 9, 16, 26 must make the former the nutrition of choice in all but a very small minority of paediatric patients.
In conclusion, this study has demonstrated that nutritional support in a paediatric BMT population can be adequately provided by a programme of aggressive enteral feeding, even in patients who have been conditioned with TBI. Ongoing participation and commitment by a multidisciplinary team, together with parents, cannot be overemphasised.
